Table 4. The frequencies of hematuria, irritative voiding symptoms, and suprapubic pain due to the toxicity of epirubicin or MMC.
|
Epirubicin |
MMC |
|||||
|---|---|---|---|---|---|---|
| Hematuria (%)* | Irritative voiding symptoms (%) | Suprapubic pain (%) | Hematuria (%) | Irritative voiding symptoms (%) | Suprapubic pain (%) | |
| GSTP1 rs1695 | ||||||
| AA | 12 (9.2) | 40 (30.8) | 14 (10.8) | 11 (9.6) | 9 (7.9) | 10 (8.8) |
| AG | 6 (4.6) | 11 (8.5) | 12 (9.2) | 10 (8.8) | 7 (6.1) | 7 (6.1) |
| GG | 1 (0.8) | 1 (0.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| GSTO1 rs4925 | ||||||
| AA | 1 (0.8) | 2 (1.5) | 1 (0.8) | 1 (0.9) | 2 (1.8) | 2 (1.8) |
| AC | 10 (7.7) | 16 (12.3) | 12 (9.2) | 5 (4.4) | 2 (1.8) | 7 (6.1) |
| CC | 8 (6.2) | 34 (26.2) | 13 (10) | 15 (13.2) | 12 (10.5) | 8 (7.0) |
*The number of patients with individual complications versus the number of patients with different instillation agents.